# Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

> **NCT02684617** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 75 (actual)

## Conditions studied

- rrCLL
- rrMM
- rrDLBCL

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **DRUG:** dinaciclib

## Key facts

- **NCT ID:** NCT02684617
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-29
- **Primary completion:** 2020-04-06
- **Final completion:** 2020-04-06
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2021-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684617, "Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02684617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*